Laurus Labs Limited has received approval from unsecured creditors for its proposed Composite Scheme of Arrangement, marking a crucial step forward in the corporate restructuring process. The pharmaceutical company announced on April 07, 2026, that creditor meetings held the previous day resulted in unanimous support for the scheme.

Creditor Meeting Details

The meetings of unsecured creditors were conducted on April 06, 2026, in accordance with directions issued by the Hon'ble National Company Law Tribunal (NCLT), Amravati Special Branch. The company confirmed that both meetings achieved the requisite quorum and were conducted in a fair and transparent manner.

Scheme Structure and Participants

The Composite Scheme of Arrangement involves three key entities within the Laurus Labs group:

• Laurus Synthesis Private Limited - Demerged Company/Transferor Company (wholly-owned subsidiary)
• Sriam Labs Private Limited - Resulting Company (wholly-owned subsidiary)
• Laurus Labs Limited - Transferee Company (parent company)

The scheme is being implemented under Sections 230 to 232 of the Companies Act, 2013, along with the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016, and other applicable regulations.

Implementation Timeline and Next Steps

The creditor approval represents a significant milestone in the scheme's implementation process. However, the arrangement remains subject to several pending approvals:

• Approval from the Hon'ble National Company Law Tribunal
• Clearances from other statutory authorities
• Additional regulatory approvals as may be applicable

The company had previously communicated about the NCLT directions in its letter dated February 24, 2026, setting the stage for the April creditor meetings.

Regulatory Compliance

Laurus Labs filed this update under Regulation 30 of the listing regulations, ensuring transparency with stakeholders regarding this material corporate development. The company emphasized that all procedural requirements were met during the creditor meetings, maintaining compliance with legal and regulatory frameworks governing such arrangements.

Laurus Labs has received a buy rating from Motilal Oswal Securities Limited (MOSL) with a target price of Rs 1280, reflecting the brokerage's confidence in the pharmaceutical company's growth trajectory and strategic positioning in key markets.

Key Growth Drivers

MOSL has identified several factors that support Laurus Labs' strong medium-term outlook:

Strategic Partnership and Market Expansion

The strategic joint venture with KRKA represents a significant development for Laurus Labs' international expansion plans. This partnership is specifically focused on formulations for the European and Asia-Pacific markets, potentially opening new revenue streams and strengthening the company's global footprint.

CDMO Business Strengthening

The deepening CDMO relationships indicate growing trust and collaboration with pharmaceutical partners. This trend suggests sustained business growth as clients increasingly rely on Laurus Labs for their development and manufacturing requirements. The dedicated capacity expansion aligns with this growing demand and positions the company to capture additional market opportunities.

ARV Segment Performance

The antiretroviral segment continues to show promise with volume-driven growth supported by stable pricing. This stability in a key therapeutic area provides a reliable foundation for the company's overall performance and contributes to the positive medium-term outlook identified by MOSL.